John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile.

Pirfenidone is under clinical development by Yungjin Pharm and currently in Phase I for Idiopathic Pulmonary Fibrosis.

Conventional drug development typically zeroes in on individual proteins or signaling pathways. By focusing on the ...

James J. Powell, 85, of Hingham, died on December 28, 2024, at the Pat Roche Hospice Home, after an extended struggle against ...

Fatty acid synthase, the enzyme responsible for fatty acid production in cells, may be a therapeutic target for IPF, a mouse ...

Anna Podolanczuk, M.D., M.S., discusses how the differential diagnosis for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is approached, the importance of early diagnosis ...

A review on the health effects of microplastics has some scientists suspecting the worst. The tiny synthetic particles that ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

A new charity football team in Peterborough has been set up to honour the memory of Jordan Smith and raise awareness of ...

Scientists at EMBL discovered that Dextromethorphan, found in common cough syrups, shows promise in treating lung fibrosis.

A longtime coach for Lemoore Youth Baseball is recovering after receiving a double lung transplant.Ivan Legarretta will spend ...

One medical institution has issued a health warning on social media about the incurable lung condition that late BBC DJ ...